AB Science

Stocks

AB

FR0010557264

Market Closed - Euronext Paris 09:25:00 18/09/2026 pm IST			Pre-market 12:12:34 pm
0.7050 ^EUR	-0.98%		0.7110	+0.85%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Transcript : AB Science S.A. - Special Call

Published on 10/16/2025 at 07:21 pm IST - Modified on 10/24/2025 at 10:36 pm IST

S&P Capital IQ

Presenter Speech
Alain Moussy (Executives)

Good morning, and good afternoon for the participant to our web conference organized by AB Science. About an update of the clinical development of our asset

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about AB Science

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study

Chart AB Science

Duration

Period

AB: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data